A large analysis of more than 2,300 patients from nine major clinical trials has found that race does not affect how well CAR T-cell therapy works for people with B-cell lymphoma. Instead, patient outcomes depend mainly on clinical factors such as overall health and how advanced the disease is at the start of treatment. When patients have equal access to care, response rates and survival are similar across Black, Asian, Hispanic, and White groups.
The study showed that patients with poorer functional status or high tumor burden had worse outcomes. Those with bulky disease had much shorter survival compared to patients without it. In addition, patients who needed extra “bridging” therapy before receiving CAR T treatment also had lower survival than those who could proceed مباشرة to infusion. These findings highlight that disease severity and patient condition play a much bigger role than race.
However, the study also found major disparities in access to treatment. About 75% of trial participants were non-Hispanic White, showing that minority groups are underrepresented. This is not due to trial selection criteria, but rather barriers such as lower referral rates to specialized centers and limited access in less affluent or rural areas. Researchers conclude that while the therapy is equally effective across all groups, improving access and referral pathways is essential to ensure fair outcomes for all patients.